BRIEF-Hemispherx Biopharma received approval of its new drug application from ANMAT
Aug 26 (Reuters) - Hemispherx Biopharma Inc
* Received approval of its new drug application from anmat for commercial sale of rintatolimod in argentine republic
* Product will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America
* Will continue to seek approval in additional Latin American countries
Source text for Eikon:
Further company coverage:
© Thomson Reuters 2017 All rights reserved.